You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCitalopram
Accession NumberDB00215  (APRD00147)
TypeSmall Molecule
GroupsApproved
DescriptionCitalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Citalopram and its N-demethylated metabolites exist as a racemic mixture but its effects are largely due to the S-enantiomer, S-citalopram and S-demthylcitalopram. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. Citalopram has the fewest drug-drug interactions of the SSRIs.
Structure
Thumb
Synonyms
Citadur
Nitalapram
External Identifiers
  • Lu 10-171
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-citalopramtablet20 mgoralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Abbott-citalopramtablet40 mgoralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Abbott-citalopramtablet10 mgoralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Accel-citalopram Tabletstablet20 mgoralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram Tabletstablet40 mgoralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram Tabletstablet10 mgoralAccel Pharma Inc2013-03-21Not applicableCanada
Act Citalopramtablet20 mgoralActavis Pharma Company2004-01-21Not applicableCanada
Act Citalopramtablet30 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Citalopramtablet40 mgoralActavis Pharma Company2004-01-21Not applicableCanada
Ag-citalopramtablet10 mgoralAngita Pharma Inc.2014-08-14Not applicableCanada
Ag-citalopramtablet20 mgoralAngita Pharma Inc.2014-09-14Not applicableCanada
Ag-citalopramtablet40 mgoralAngita Pharma Inc.2014-09-14Not applicableCanada
Auro-citalopramtablet20 mgoralAuro Pharma Inc2011-11-28Not applicableCanada
Auro-citalopramtablet40 mgoralAuro Pharma Inc2011-11-28Not applicableCanada
Ava-citalopramtablet10 mgoralAvanstra Inc2011-11-232014-08-21Canada
Bio-citalopramtablet10 mgoralBiomed Pharma2016-07-29Not applicableCanada
Bio-citalopramtablet20 mgoralBiomed Pharma2016-07-29Not applicableCanada
Bio-citalopramtablet40 mgoralBiomed Pharma2016-07-29Not applicableCanada
Celexatablet, film coated10 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexatablet20 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Celexatablet, film coated20 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexatablet40 mg/1oralPhysicians Total Care, Inc.2001-09-05Not applicableUs
Celexatablet, film coated40 mg/1oralForest Laboratories, Inc.1998-07-17Not applicableUs
Celexatablet10 mg/1oralPhysicians Total Care, Inc.2004-01-30Not applicableUs
Celexatablet, film coated40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Celexa 10 mgtablet10 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Celexa 20 mgtablet20 mgoralLundbeck Canada Inc1999-03-08Not applicableCanada
Celexa 40 mgtablet40 mgoralLundbeck Canada Inc1999-03-08Not applicableCanada
Citalopramtablet40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Citalopramtablet20 mgoralSanis Health Inc2010-07-30Not applicableCanada
Citalopramtablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopramtablet10 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet10 mgoralMeliapharm Inc2009-02-262014-06-26Canada
Citalopramtablet20 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet10 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet40 mgoralSanis Health Inc2010-07-30Not applicableCanada
Citalopramtablet20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopramtablet20 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Citalopramtablet20 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet40 mgoralJamp Pharma Corporation2014-09-10Not applicableCanada
Citalopramtablet10 mgoralSanis Health Inc2015-10-14Not applicableCanada
Citalopramtablet20 mgoralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
Citalopramtablet40 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Citalopramtablet40 mgoralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
Citalopramtablet40 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Citalopramtablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Citalopramtablet40 mgoralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
Citalopram Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram Tabletstablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram Tablets USPtablet10 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPtablet20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPtablet40 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram-10tablet10 mgoralPro Doc Limitee2009-06-25Not applicableCanada
Citalopram-20tablet20 mgoralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-40tablet40 mgoralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-odantablet20 mgoralOdan Laboratories Ltd2008-05-082015-11-10Canada
Citalopram-odantablet40 mgoralOdan Laboratories Ltd2008-05-082015-11-10Canada
Ctp 30tablet30 mgoralSunovion Pharmaceuticals Canada Inc2007-10-31Not applicableCanada
Dom-citalopramtablet10 mgoralDominion Pharmacal2006-02-21Not applicableCanada
Dom-citalopramtablet20 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-citalopramtablet40 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Ecl-citalopramtablet20 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramtablet40 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramtablet10 mgoralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ipg-citalopramtablet10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-citalopramtablet20 mgoralInternational Pharmaceutical Generics Ltd2008-06-26Not applicableCanada
Ipg-citalopramtablet40 mgoralInternational Pharmaceutical Generics Ltd2008-06-26Not applicableCanada
Jamp-citalopramtablet20 mgoralJamp Pharma Corporation2008-09-12Not applicableCanada
Jamp-citalopramtablet10 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-citalopramtablet40 mgoralJamp Pharma Corporation2008-09-12Not applicableCanada
Manda-citalopramtablet20 mgoralManda Pharma Inc2012-06-012013-08-22Canada
Manda-citalopramtablet40 mgoralManda Pharma Inc2012-06-012013-08-22Canada
Manda-citalopramtablet10 mgoralManda Pharma Inc2012-07-032013-08-22Canada
Mar-citalopramtablet10 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramtablet20 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramtablet40 mgoralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mint-citalopramtablet20 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramtablet40 mgoralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramtablet40 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramtablet10 mgoralMint Pharmaceuticals Inc2011-09-13Not applicableCanada
Mint-citalopramtablet20 mgoralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramtablet10 mgoralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mylan-citalopramtablet10 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-citalopramtablet20 mgoralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Mylan-citalopramtablet40 mgoralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Nat-citalopramtablet10 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramtablet20 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramtablet40 mgoralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopram Tabletstablet40 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Nat-citalopram Tabletstablet20 mgoralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Ng Citalopramtablet20 mgoralNext Generation Pharma Inc2009-08-142011-08-30Canada
Ng Citalopramtablet40 mgoralNext Generation Pharma Inc2009-08-142011-08-30Canada
Novo-citalopramtablet20 mgoralNovopharm Limited2004-08-272011-11-08Canada
Novo-citalopramtablet40 mgoralNovopharm Limited2004-08-272011-11-08Canada
Ntp-citalopramtablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramtablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramtablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-citalopramtablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-citalopramtablet40 mgoralNu Pharm IncNot applicableNot applicableCanada
Pendo-citalopramtablet20 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-citalopramtablet20 mgoralPharmel Inc2004-04-06Not applicableCanada
PHL-citalopramtablet40 mgoralPharmel Inc2004-04-06Not applicableCanada
PHL-citalopramtablet10 mgoralPharmel Inc2006-03-13Not applicableCanada
PMS-citalopramtablet20 mgoralPharmascience Inc2004-01-15Not applicableCanada
PMS-citalopramtablet10 mgoralPharmascience Inc2005-09-10Not applicableCanada
PMS-citalopramtablet40 mgoralPharmascience Inc2004-01-15Not applicableCanada
Priva-citalopramtablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramtablet40 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramtablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Q-citalopramtablet10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramtablet40 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramtablet20 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ran-citalotablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citalotablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ran-citalopramtablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ratio-citalopramtablet20 mgoralTeva Canada Limited2004-04-262012-12-21Canada
Ratio-citalopramtablet40 mgoralTeva Canada Limited2004-04-262012-12-21Canada
Riva-citalopramtablet20 mgoralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramtablet40 mgoralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramtablet10 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-citalopramtablet20 mgoralLaboratoire Riva Inc2004-03-242014-07-29Canada
Riva-citalopramtablet40 mgoralLaboratoire Riva Inc2004-03-242013-07-31Canada
Riva-citalopramtablet10 mgoralLaboratoire Riva Inc2008-01-24Not applicableCanada
Sandoz Citalopramtablet20 mgoralSandoz Canada Incorporated2004-01-30Not applicableCanada
Sandoz Citalopramtablet40 mgoralSandoz Canada Incorporated2004-01-30Not applicableCanada
Septa-citalopramtablet20 mgoralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Septa-citalopramtablet10 mgoralSepta Pharmaceuticals Inc2015-09-18Not applicableCanada
Septa-citalopramtablet40 mgoralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Teva-citalopramtablet20 mgoralTeva Canada Limited2007-09-19Not applicableCanada
Teva-citalopramtablet40 mgoralTeva Canada Limited2007-12-03Not applicableCanada
Teva-citalopramtablet10 mgoralTeva Canada Limited2008-12-15Not applicableCanada
Van-citalopramtablet20 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramtablet40 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramtablet10 mgoralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-citalopramtablet20 mgoralApotex Inc2004-01-21Not applicableCanada
Apo-citalopramtablet40 mgoralApotex Inc2004-01-21Not applicableCanada
Citalopramtablet, film coated40 mg/1oralPhysicians Total Care, Inc.2007-01-22Not applicableUs
Citalopramtablet20 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet40 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Citalopramtablet, film coated20 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2015-07-22Not applicableUs
Citalopramtablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Citalopramtablet40 mg/1oralMed Vantx, Inc.2012-04-24Not applicableUs
Citalopramtablet20 mg/1oralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
Citalopramtablet40 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramsolution10 mg/5mLoralRoxane Laboratories, Inc2004-05-25Not applicableUs
Citalopramtablet20 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralProficient Rx LP2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Citalopramtablet20 mg/1oralH.J. Harkins Company, Inc.2009-01-01Not applicableUs
Citalopramtablet10 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet20 mg/1oralAmerican Health Packaging2013-07-252015-12-31Us
Citalopramtablet10 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet10 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Citalopramtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-11-08Not applicableUs
Citalopramtablet40 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet40 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet10 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Citalopramtablet, film coated20 mg/1oralProficient Rx LP2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralInternational Laboratories, Inc.2008-06-25Not applicableUs
Citalopramtablet40 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Citalopramtablet, film coated20 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet, film coated10 mg/1oralRed Pharm Drug Inc.2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralPhysicians Total Care, Inc.2008-01-18Not applicableUs
Citalopramtablet40 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet, film coated40 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralMed Vantx, Inc.2007-11-08Not applicableUs
Citalopramtablet40 mg/1oralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
Citalopramtablet, film coated40 mg/1oralInternational Laboratories, Inc.2014-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet, film coated40 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramtablet20 mg/1oralTeva Pharmaceuticals USA Inc2007-02-222016-02-29Us
Citalopramtablet40 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet20 mg/1oralMed Vantx, Inc.2007-02-22Not applicableUs
Citalopramtablet10 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet, film coated40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet20 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Citalopramtablet40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Citalopramtablet10 mg/1oralAmerican Health Packaging2013-07-252015-12-29Us
Citalopramtablet10 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopramtablet20 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet20 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet, film coated10 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
Citalopramtablet, film coated10 mg/1oralAmerican Health Packaging2014-04-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet20 mg/1oralMc Kesson Contract Packaging2011-09-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralInternational Laboratories, Inc.2008-06-25Not applicableUs
Citalopramtablet20 mg/1oralClinical Solutions Wholesale2009-01-01Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2014-12-15Not applicableUs
Citalopramtablet, film coated40 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Citalopramtablet, film coated10 mg/1oralPhysicians Total Care, Inc.2010-01-14Not applicableUs
Citalopramtablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Citalopramtablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
Citalopramtablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-01-01Not applicableUs
Citalopramtablet10 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet10 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet20 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralG&W Laboratories, Inc.2015-12-02Not applicableUs
Citalopramtablet20 mg/1oralInternational Labs, Inc.2013-08-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet40 mg/1oralClinical Solutions Wholesale, Llc2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralTeva Pharmaceuticals USA Inc2007-11-082016-03-31Us
Citalopramtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
Citalopramtablet40 mg/1oralREMEDYREPACK INC.2013-03-04Not applicableUs
Citalopramtablet, film coated40 mg/1oralContract Pharmacy Services Pa2010-04-07Not applicableUs
Citalopramtablet20 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet, film coated20 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet20 mg/1oralPreferred Pharmaceuticals, Inc2011-02-09Not applicableUs
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopramtablet20 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopramtablet40 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Citalopramtablet40 mg/1oralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
Citalopramtablet, film coated40 mg/1oralREMEDYREPACK INC.2015-05-15Not applicableUs
Citalopramtablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
Citalopramtablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet20 mg/1oralReady Meds2011-01-01Not applicableUs
Citalopramtablet40 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Citalopramtablet, film coated20 mg/1oralAmerican Health Packaging2014-04-01Not applicableUs
Citalopramtablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopramtablet40 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Citalopramtablet20 mg/1oralBlenheim Pharmacal, Inc.2010-07-06Not applicableUs
Citalopramtablet10 mg/1oralCardinal Health2011-01-19Not applicableUs
Citalopramtablet40 mg/1oralClinical Solutions Wholesale2007-11-08Not applicableUs
Citalopramtablet, film coated10 mg/1oralRebel Distributors Corp.2007-03-27Not applicableUs
Citalopramtablet10 mg/1oralTeva Pharmaceuticals USA Inc2007-02-222015-11-30Us
Citalopramtablet, film coated40 mg/1oralBlenheim Pharmacal, Inc.2011-05-20Not applicableUs
Citalopramtablet, film coated40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
Citalopramtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
Citalopramtablet40 mg/1oralRebel Distributors Corp2011-01-01Not applicableUs
Citalopramtablet20 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
Citalopramtablet20 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Citalopramtablet40 mg/1oralLegacy Pharmaceutical Packaging2010-04-30Not applicableUs
Citalopramtablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-03-04Not applicableUs
Citalopramtablet, film coated10 mg/1oralDIRECT RX2016-03-22Not applicableUs
Citalopramtablet, film coated10 mg/1oralCardinal Health2013-02-08Not applicableUs
Citalopramtablet, film coated10 mg/1oralEon Labs, Inc.2004-10-28Not applicableUs
Citalopramtablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
Citalopramtablet40 mg/1oralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
Citalopramtablet, film coated10 mg/1oralApotex Corp.2011-08-01Not applicableUs
Citalopramtablet10 mg/1oralCamber Pharmaceuticals2011-01-01Not applicableUs
Citalopramtablet, film coated10 mg/1oralEpic Pharma, LLC2011-05-20Not applicableUs
Citalopramtablet, film coated40 mg/1oralAurobindo Pharma Limited2004-10-28Not applicableUs
Citalopramtablet, film coated20 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Citalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-05-28Not applicableUs
Citalopramtablet40 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-17Not applicableUs
Citalopramtablet40 mg/1oralAurolife Pharma LLC2009-01-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralTYA Pharmaceuticals2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-16Not applicableUs
Citalopram Hydrobromidetablet, film coated10 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralAurobindo Pharma Limited2006-08-28Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-10-04Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-07-22Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralLegacy Pharmaceutical Packaging2010-10-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralCardinal Health2004-11-24Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2015-07-27Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralTYA Pharmaceuticals2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs
Citalopram Hydrobromidetablet40 mg/301oralNorthwind Pharmaceuticals2014-04-03Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralProficient Rx LP2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralPreferred Pharmaceuticals Inc.2016-01-04Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralCitron Pharma LLC2006-08-28Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-07-25Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralUnit Dose Services2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralCardinal Health2004-11-24Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralREMEDYREPACK INC.2010-12-16Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralREMEDYREPACK INC.2011-04-26Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralSt Marys Medical Park Pharmacy2007-10-18Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralCamber Pharmaceuticals, Inc.2015-12-21Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralProficient Rx LP2007-10-18Not applicableUs
Citalopram Hydrobromidetablet, film coated20 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2011-07-28Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2014-02-20Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram Hydrobromidesolution10 mg/5mLoralSilarx Pharmaceuticals, Inc2006-06-14Not applicableUs
Citalopram Hydrobromidetablet, film coated10 mg/1oralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2014-12-29Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralStat Rx USA2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram Hydrobromidetablet, film coated40 mg/1oralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralContract Pharmacy Services Pa2009-09-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralDIRECT RX2014-01-01Not applicableUs
Citalopram Hydrobromidetablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralREMEDYREPACK INC.2011-08-08Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram Hydrobromidetablet10 mg/1oralCardinal Health2009-11-02Not applicableUs
Citalopram Hydrobromidetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Direct Rxtablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Direct Rxtablet40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Perrigo Citalopramtablet20 mg/1oralContract Pharmacy Services Pa2010-02-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkarinNot Available
CelapramNot Available
CiazilNot Available
CiliftNot Available
CipramNot Available
CipramilNot Available
CiprapineNot Available
CitabaxNot Available
CitalecNot Available
CitolNot Available
CitopamNot Available
CitoxNot Available
CitrolNot Available
DalsanNot Available
ElopramNot Available
HumorupNot Available
OropramNot Available
PramcitNot Available
RecitalNot Available
SeropramNot Available
TalamNot Available
TalohexalNot Available
TemperaxNot Available
VodelaxNot Available
ZentiusNot Available
ZetaloNot Available
Brand mixtures
NameLabellerIngredients
Sentralopram Am-10Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Citalopram Hydrobromide
59729-32-7
Thumb
  • InChI Key: WIHMBLDNRMIGDW-UHFFFAOYNA-N
  • Monoisotopic Mass: 404.089954188
  • Average Mass: 405.304
DBSALT000027
Categories
UNII0DHU5B8D6V
CAS number59729-33-8
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyInChIKey=WSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
IUPAC Name
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy.
PharmacodynamicsCitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (α1, α2, β), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionRapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption.
Volume of distribution
  • 12 L/kg
    Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, demethylcitalopram does not cross the barrier well.
Protein bindingCitalopram, dimethylcitalopram, and didemethylcitalopram is 80% bound to plasma proteins.
Metabolism

Citalopram is metabolized mainly in the liver via N-demethylation to its principle metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram N-oxide, and a deaminated propionic acid derivative. However, the predominant entity in plasma is unchanged citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further N-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug.

SubstrateEnzymesProduct
Citalopram
Citalopram N-oxideDetails
Citalopram
N-DesmethylcitalopramDetails
Citalopram
Not Available
Citalopram propionic acidDetails
N-Desmethylcitalopram
N,N-DidesmethylcitalopramDetails
Route of elimination12-23% of an oral dose of citalopram is recovered unchanged in the urine, while 10% of the dose is recovered in the feces.
Half life35 hours
Clearance

The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.

ToxicitySymptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Citalopram Action PathwayDrug actionSMP00424
Citalopram Metabolism PathwayDrug metabolismSMP00627
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 2A
Gene symbol: HTR2A
UniProt: P28223
rs7997012 Not AvailableA AlleleImproved response to antidepressant medication16642436
Glutamate receptor ionotropic, kainate 4
Gene symbol: GRIK4
UniProt: Q16099
rs1954787 Not AvailableC AlleleImproved response to antidepressant medication17671280
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableG AlleleHomozygosity for the rs6295 G allele is associated with lower response rate in patients treated for major depression19829169
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Glutamate receptor ionotropic, kainate 2
Gene symbol: GRIK2
UniProt: Q13002
rs2518224 Not AvailableC Allele, homozygoteIncreased suicidal thoughts17898344
Glutamate receptor 3
Gene symbol: GRIA3
UniProt: P42263
rs4825476 Not AvailableG Allele, homozygoteIncreased suicidal thoughts17898344
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs4675690 Not AvailableT AlleleElevated suicide risk17548750
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs7569963 Not AvailableA AlleleElevated suicide risk17548750
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alphapharm party ltd
  • Forest laboratories inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd inc
  • Roxane laboratories inc
  • Silarx pharmaceuticals inc
  • Biovail laboratories international srl
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Matrix laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Natco pharma ltd
  • Pliva inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Torrent pharmaceuticals ltd
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral20 mg
Tabletoral40 mg
Solutionoral10 mg/5mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tabletoral40 mg/301
Tabletoral30 mg
Tabletoral10 mg
Kit
Prices
Unit descriptionCostUnit
Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle122.28USD bottle
Celexa 40 mg tablet3.88USD tablet
Celexa 20 mg tablet3.72USD tablet
Celexa 10 mg tablet3.57USD tablet
Citalopram Hydrobromide 40 mg tablet2.89USD tablet
Citalopram Hydrobromide 20 mg tablet2.8USD tablet
Citalopram Hydrobromide 10 mg tablet2.68USD tablet
Citalopram hbr 40 mg tablet2.53USD tablet
Citalopram hbr 20 mg tablet2.43USD tablet
Citalopram hbr 10 mg tablet2.33USD tablet
Celexa 20 mg Tablet1.47USD tablet
Celexa 40 mg Tablet1.47USD tablet
Ctp 30 30 mg Tablet0.99USD tablet
Apo-Citalopram 20 mg Tablet0.82USD tablet
Apo-Citalopram 40 mg Tablet0.82USD tablet
Citalopram 20 mg Tablet0.82USD tablet
Citalopram 40 mg Tablet0.82USD tablet
Citalopram-Odan 20 mg Tablet0.82USD tablet
Citalopram-Odan 40 mg Tablet0.82USD tablet
Co Citalopram 20 mg Tablet0.82USD tablet
Co Citalopram 40 mg Tablet0.82USD tablet
Jamp-Citalopram 20 mg Tablet0.82USD tablet
Jamp-Citalopram 40 mg Tablet0.82USD tablet
Mint-Citalopram 20 mg Tablet0.82USD tablet
Mint-Citalopram 40 mg Tablet0.82USD tablet
Mylan-Citalopram 20 mg Tablet0.82USD tablet
Mylan-Citalopram 40 mg Tablet0.82USD tablet
Ng Citalopram 20 mg Tablet0.82USD tablet
Ng Citalopram 40 mg Tablet0.82USD tablet
Novo-Citalopram 20 mg Tablet0.82USD tablet
Novo-Citalopram 40 mg Tablet0.82USD tablet
Phl-Citalopram 20 mg Tablet0.82USD tablet
Phl-Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 20 mg Tablet0.82USD tablet
Pms-Citalopram 40 mg Tablet0.82USD tablet
Ran-Citalo 20 mg Tablet0.82USD tablet
Ran-Citalo 40 mg Tablet0.82USD tablet
Ran-Citalopram 20 mg Tablet0.82USD tablet
Ran-Citalopram 40 mg Tablet0.82USD tablet
Ratio-Citalopram 20 mg Tablet0.82USD tablet
Ratio-Citalopram 40 mg Tablet0.82USD tablet
Sandoz Citalopram 20 mg Tablet0.82USD tablet
Sandoz Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 10 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2049368 No2001-10-232011-08-16Canada
CA2353693 No2003-07-222021-07-24Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point182-183 °CNot Available
water solubilitySparingly soluble FDA label
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9110000000-5b1fde1b7a58929c7f2dView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Hans Petersen, “Method for the preparation of citalopram.” U.S. Patent US6229026, issued December, 1992.

US6229026
General References
  1. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. [PubMed:1424428 ]
  2. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5. [PubMed:12494286 ]
  3. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9. [PubMed:8104273 ]
  4. Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20. [PubMed:16430968 ]
  5. Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11. [PubMed:8732438 ]
  6. Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60. [PubMed:1632943 ]
  7. Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302. [PubMed:9571301 ]
External Links
ATC CodesN06AB04
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (148 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Citalopram.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Citalopram.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Citalopram.
AbirateroneThe metabolism of Citalopram can be decreased when combined with Abiraterone.
AcarboseCitalopram may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Citalopram.
AcenocoumarolCitalopram may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Citalopram.
AcetaminophenThe serum concentration of Citalopram can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Citalopram.
Acetylsalicylic acidCitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Citalopram.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Citalopram.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Citalopram.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Citalopram.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Citalopram.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Citalopram.
AlbendazoleThe serum concentration of Citalopram can be increased when it is combined with Albendazole.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Citalopram.
AlbiglutideCitalopram may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Citalopram can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Citalopram.
AlectinibThe serum concentration of Citalopram can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.
AlfentanilAlfentanil may increase the serotonergic activities of Citalopram.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Citalopram.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Citalopram.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Citalopram.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Citalopram.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Citalopram.
AlogliptinCitalopram may increase the hypoglycemic activities of Alogliptin.
AlosetronThe metabolism of Alosetron can be decreased when combined with Citalopram.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Citalopram.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Citalopram.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Citalopram.
AmantadineThe serum concentration of Citalopram can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Citalopram.
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.
Aminohippuric acidThe serum concentration of Citalopram can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Citalopram.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Citalopram.
AmiodaroneCitalopram may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Citalopram.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Citalopram.
AmlodipineThe serum concentration of Citalopram can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Citalopram.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Citalopram.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Citalopram.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Citalopram.
AmprenavirThe serum concentration of Citalopram can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Citalopram.
AmsacrineThe serum concentration of Citalopram can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Citalopram.
AnagrelideCitalopram may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Citalopram.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Citalopram.
ApomorphineApomorphine may increase the QTc-prolonging activities of Citalopram.
AprepitantThe serum concentration of Citalopram can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Citalopram.
AprindineThe metabolism of Aprindine can be decreased when combined with Citalopram.
ArformoterolArformoterol may increase the QTc-prolonging activities of Citalopram.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Citalopram.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Citalopram.
ArmodafinilThe metabolism of Citalopram can be decreased when combined with Armodafinil.
Arsenic trioxideCitalopram may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherCitalopram may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Citalopram.
ASA404The metabolism of ASA404 can be decreased when combined with Citalopram.
AsenapineCitalopram may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Citalopram can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Citalopram.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Citalopram.
AtenololThe serum concentration of Citalopram can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Citalopram can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Citalopram can be increased when it is combined with Atorvastatin.
AV650The metabolism of AV650 can be decreased when combined with Citalopram.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Citalopram.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Citalopram.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Citalopram.
AzelastineThe metabolism of Azelastine can be decreased when combined with Citalopram.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Citalopram.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Citalopram.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Citalopram.
BendamustineThe metabolism of Bendamustine can be decreased when combined with Citalopram.
BendroflumethiazideCitalopram may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Citalopram.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Citalopram.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Citalopram.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Citalopram.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Citalopram.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Citalopram.
BepridilThe serum concentration of Citalopram can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Citalopram.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Citalopram.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Citalopram.
BexaroteneThe serum concentration of Citalopram can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Citalopram.
BifeprunoxThe risk or severity of adverse effects can be increased when Citalopram is combined with Bifeprunox.
BiperidenThe serum concentration of Citalopram can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Citalopram.
BoceprevirThe metabolism of Citalopram can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Citalopram.
BortezomibThe metabolism of Citalopram can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Citalopram.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Citalopram.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Citalopram.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Citalopram.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Citalopram.
BromocriptineCitalopram may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe serum concentration of Citalopram can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Citalopram.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Citalopram.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Citalopram.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Citalopram.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Citalopram.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Citalopram.
BuprenorphineBuprenorphine may increase the serotonergic activities of Citalopram.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Citalopram.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Citalopram.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.
BuserelinBuserelin may increase the QTc-prolonging activities of Citalopram.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Citalopram.
BuspironeThe metabolism of Buspirone can be decreased when combined with Citalopram.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Citalopram.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Citalopram.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Citalopram.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Citalopram.
ButorphanolButorphanol may increase the serotonergic activities of Citalopram.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Citalopram.
CabergolineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cabergoline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Citalopram.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Citalopram.
CanagliflozinCitalopram may increase the hypoglycemic activities of Canagliflozin.
CanagliflozinThe serum concentration of Citalopram can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Citalopram can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Citalopram can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Citalopram.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Citalopram.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Citalopram.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Citalopram.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Citalopram.
CarfentanilCarfentanil may increase the serotonergic activities of Citalopram.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Citalopram.
CariprazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Citalopram.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Citalopram.
CarmustineThe metabolism of Carmustine can be decreased when combined with Citalopram.
CaroxazoneCaroxazone may increase the serotonergic activities of Citalopram.
CarteololThe metabolism of Carteolol can be decreased when combined with Citalopram.
CarvedilolThe serum concentration of Citalopram can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Citalopram.
CaspofunginThe serum concentration of Citalopram can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Citalopram can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Citalopram.
CeritinibCeritinib may increase the QTc-prolonging activities of Citalopram.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Citalopram.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Citalopram.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Citalopram.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram.
ChloramphenicolThe serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Citalopram.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Citalopram.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Citalopram.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Citalopram.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Citalopram.
ChloroquineChloroquine may increase the QTc-prolonging activities of Citalopram.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Citalopram.
ChlorothiazideCitalopram may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Citalopram.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Citalopram.
ChlorpromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Chlorpromazine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Citalopram.
ChlorpropamideCitalopram may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Citalopram can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Citalopram.
ChlorthalidoneCitalopram may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Citalopram.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Citalopram.
CholecalciferolThe metabolism of Citalopram can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Citalopram can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Citalopram can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Citalopram can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Citalopram.
CimetidineThe serum concentration of Citalopram can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Citalopram.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Citalopram.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Citalopram.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Citalopram.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Citalopram.
CisaprideCitalopram may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Citalopram.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Citalopram.
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Citalopram.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Citalopram.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Citalopram.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Citalopram.
ClofazimineThe serum concentration of Citalopram can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Citalopram.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Citalopram.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Citalopram.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Citalopram.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Citalopram.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Citalopram.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Citalopram.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Citalopram.
ClotrimazoleThe metabolism of Citalopram can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Citalopram is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Citalopram.
CobicistatThe serum concentration of Citalopram can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Citalopram.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Citalopram.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Citalopram.
CodeineCodeine may increase the serotonergic activities of Citalopram.
ColchicineThe serum concentration of Citalopram can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Citalopram can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Citalopram can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Citalopram.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Citalopram.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Citalopram.
CyamemazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Citalopram.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Citalopram.
CyclophosphamideThe serum concentration of Citalopram can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Citalopram.
CyclosporineThe metabolism of Citalopram can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Citalopram.
CyproheptadineThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.
Cyproterone acetateThe serum concentration of Citalopram can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Citalopram.
DabrafenibThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Citalopram.
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Citalopram.
DaclatasvirThe serum concentration of Citalopram can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Citalopram can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.
DapagliflozinCitalopram may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Citalopram.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.
DapoxetineCitalopram may increase the serotonergic activities of Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Citalopram.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Citalopram.
DarunavirThe serum concentration of Citalopram can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Citalopram.
DasatinibThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Citalopram can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Citalopram.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Citalopram.
DeferasiroxThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Citalopram.
DelavirdineThe metabolism of Citalopram can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Citalopram.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Citalopram.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.
DesipramineThe metabolism of Desipramine can be decreased when combined with Citalopram.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Citalopram.
DesmopressinThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Citalopram.
DexamethasoneThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Citalopram.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Citalopram.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Citalopram.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Citalopram.
DextromethorphanThe serum concentration of Citalopram can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Citalopram.
DextromoramideDextromoramide may increase the serotonergic activities of Citalopram.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Citalopram.
DezocineDezocine may increase the serotonergic activities of Citalopram.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Citalopram.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Citalopram.
DiclofenacThe serum concentration of Citalopram can be increased when it is combined with Diclofenac.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Citalopram.
DicoumarolCitalopram may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Citalopram.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Citalopram.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Citalopram.
DigoxinThe serum concentration of Citalopram can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Citalopram.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Citalopram.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.
DihydroergotamineThe metabolism of Citalopram can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Citalopram.
DihydromorphineDihydromorphine may increase the serotonergic activities of Citalopram.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Citalopram.
DiltiazemThe metabolism of Citalopram can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Citalopram.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram.
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Citalopram.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Citalopram.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Citalopram.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Citalopram.
DipyridamoleThe serum concentration of Citalopram can be increased when it is combined with Dipyridamole.
DisopyramideCitalopram may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Citalopram can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Citalopram.
DofetilideDofetilide may increase the QTc-prolonging activities of Citalopram.
DolasetronDolasetron may increase the QTc-prolonging activities of Citalopram.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Citalopram.
DomperidoneCitalopram may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Citalopram.
DopamineThe metabolism of Dopamine can be decreased when combined with Citalopram.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Citalopram.
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Citalopram.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Citalopram.
DoxazosinThe serum concentration of Citalopram can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Citalopram.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
DoxepinThe metabolism of Doxepin can be decreased when combined with Citalopram.
DoxorubicinThe serum concentration of Citalopram can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Citalopram.
DoxycyclineThe metabolism of Citalopram can be decreased when combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram.
DPDPEDPDPE may increase the serotonergic activities of Citalopram.
DronabinolThe serum concentration of Citalopram can be increased when it is combined with Dronabinol.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Citalopram.
DronedaroneCitalopram may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Droperidol.
DroperidolDroperidol may increase the QTc-prolonging activities of Citalopram.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram.
DulaglutideCitalopram may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Citalopram.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Citalopram.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Citalopram.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Citalopram.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Citalopram.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Citalopram.
ElbasvirThe serum concentration of Citalopram can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Citalopram.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Citalopram.
EliglustatCitalopram may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Citalopram.
EmpagliflozinCitalopram may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe serum concentration of Citalopram can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Citalopram.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Citalopram.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Citalopram.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Citalopram.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.
EnzalutamideThe serum concentration of Citalopram can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Citalopram.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.
ErgonovineThe serum concentration of Citalopram can be increased when it is combined with Ergonovine.
ErgonovineThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.
ErgotamineThe serum concentration of Citalopram can be increased when it is combined with Ergotamine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Citalopram.
EribulinEribulin may increase the QTc-prolonging activities of Citalopram.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Citalopram.
ErythromycinErythromycin may increase the QTc-prolonging activities of Citalopram.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Citalopram.
EscitalopramCitalopram may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Citalopram can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Citalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Citalopram.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Citalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Citalopram.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Citalopram.
EstramustineThe serum concentration of Citalopram can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Citalopram can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Citalopram.
EstroneThe serum concentration of Citalopram can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Citalopram.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Citalopram.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Citalopram.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Citalopram.
EthanolThe metabolism of Ethanol can be decreased when combined with Citalopram.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Citalopram.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.
Ethyl biscoumacetateCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram.
EthylmorphineEthylmorphine may increase the serotonergic activities of Citalopram.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Citalopram.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Citalopram.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Citalopram.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Citalopram.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.
EtoperidoneCitalopram may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Citalopram can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Citalopram.
EtorphineEtorphine may increase the serotonergic activities of Citalopram.
EtravirineThe serum concentration of Citalopram can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Citalopram.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Citalopram.
ExenatideCitalopram may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Citalopram.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Citalopram.
FamotidineFamotidine may increase the QTc-prolonging activities of Citalopram.
FamotidineThe metabolism of Famotidine can be decreased when combined with Citalopram.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Citalopram.
FelodipineThe serum concentration of Citalopram can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Citalopram.
FenfluramineCitalopram may increase the serotonergic activities of Fenfluramine.
FentanylFentanyl may increase the serotonergic activities of Citalopram.
FentanylThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Citalopram.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Citalopram.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Citalopram.
FingolimodFingolimod may increase the QTc-prolonging activities of Citalopram.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Citalopram.
FlecainideFlecainide may increase the QTc-prolonging activities of Citalopram.
FlecainideThe metabolism of Flecainide can be decreased when combined with Citalopram.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.
FluconazoleFluconazole may increase the QTc-prolonging activities of Citalopram.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Citalopram.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Citalopram.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Citalopram.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Citalopram.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Citalopram.
FluoxetineCitalopram may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolCitalopram may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Citalopram.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Citalopram.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Citalopram.
FlutamideThe metabolism of Flutamide can be decreased when combined with Citalopram.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Citalopram.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Citalopram.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Citalopram.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Citalopram.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Citalopram.
FormoterolFormoterol may increase the QTc-prolonging activities of Citalopram.
FormoterolThe metabolism of Formoterol can be decreased when combined with Citalopram.
FosamprenavirThe metabolism of Citalopram can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Citalopram can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Citalopram.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Citalopram.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Citalopram.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Citalopram.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Citalopram.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Citalopram.
FurazolidoneFurazolidone may increase the serotonergic activities of Citalopram.
Fusidic AcidThe serum concentration of Citalopram can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Citalopram.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Citalopram.
GalantamineThe metabolism of Galantamine can be decreased when combined with Citalopram.
GalantamineGalantamine may increase the QTc-prolonging activities of Citalopram.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Citalopram.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Citalopram.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Citalopram.
GemfibrozilThe serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Citalopram.
GenisteinThe serum concentration of Citalopram can be increased when it is combined with Genistein.
GenisteinThe metabolism of Genistein can be decreased when combined with Citalopram.
GliclazideCitalopram may increase the hypoglycemic activities of Gliclazide.
GlimepirideCitalopram may increase the hypoglycemic activities of Glimepiride.
GlipizideCitalopram may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Citalopram.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Citalopram.
GlyburideCitalopram may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Citalopram can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Citalopram can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Citalopram.
Gramicidin DThe serum concentration of Citalopram can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Citalopram.
GranisetronThe metabolism of Granisetron can be decreased when combined with Citalopram.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Citalopram.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Citalopram.
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Citalopram.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Citalopram.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Citalopram.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Citalopram.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Citalopram.
HaloperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Haloperidol.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Citalopram.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Citalopram.
HalothaneThe metabolism of Halothane can be decreased when combined with Citalopram.
HeroinHeroin may increase the serotonergic activities of Citalopram.
HesperetinThe metabolism of Hesperetin can be decreased when combined with Citalopram.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Citalopram.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Citalopram.
HistrelinHistrelin may increase the QTc-prolonging activities of Citalopram.
HydracarbazineHydracarbazine may increase the serotonergic activities of Citalopram.
HydrochlorothiazideCitalopram may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Citalopram.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Citalopram.
HydrocortisoneThe serum concentration of Citalopram can be increased when it is combined with Hydrocortisone.
HydroflumethiazideCitalopram may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Citalopram.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Citalopram.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Citalopram.
IbandronateIbandronate may increase the QTc-prolonging activities of Citalopram.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Citalopram.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Citalopram.
IbutilideCitalopram may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Citalopram.
IdelalisibThe serum concentration of Citalopram can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Citalopram.
IloperidoneCitalopram may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Citalopram can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Citalopram.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Citalopram.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Citalopram.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Citalopram.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Citalopram.
IndalpineCitalopram may increase the serotonergic activities of Indalpine.
IndapamideCitalopram may increase the hyponatremic activities of Indapamide.
IndapamideIndapamide may increase the QTc-prolonging activities of Citalopram.
IndinavirThe serum concentration of Citalopram can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Citalopram.
IndomethacinThe serum concentration of Citalopram can be increased when it is combined with Indomethacin.
Insulin AspartCitalopram may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirCitalopram may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineCitalopram may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineCitalopram may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanCitalopram may increase the hypoglycemic activities of Insulin Human.
Insulin LisproCitalopram may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Citalopram may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.
IproclozideIproclozide may increase the serotonergic activities of Citalopram.
IproniazidIproniazid may increase the serotonergic activities of Citalopram.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Citalopram.
IsavuconazoniumThe metabolism of Citalopram can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Citalopram.
IsocarboxazidThe risk or severity of adverse effects can be increased when Citalopram is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Citalopram.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Citalopram.
IsoniazidThe metabolism of Citalopram can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Citalopram can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Citalopram can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Citalopram.
IvacaftorThe serum concentration of Citalopram can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Citalopram can be increased when it is combined with Ivermectin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Citalopram.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Citalopram.
KetamineThe metabolism of Ketamine can be decreased when combined with Citalopram.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Citalopram.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Citalopram.
KetobemidoneKetobemidone may increase the serotonergic activities of Citalopram.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Citalopram.
KetoconazoleThe serum concentration of Citalopram can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Citalopram.
LabetalolThe metabolism of Labetalol can be decreased when combined with Citalopram.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Citalopram.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Citalopram.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Citalopram.
LanreotideCitalopram may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Citalopram can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Citalopram can be increased when it is combined with Lapatinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Citalopram.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Citalopram.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Citalopram.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Citalopram.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Citalopram.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Citalopram.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Citalopram.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Citalopram.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Citalopram.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Citalopram.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Citalopram.
LevodopaThe metabolism of Levodopa can be decreased when combined with Citalopram.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Citalopram.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Citalopram.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Citalopram.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Citalopram.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Citalopram.
LevorphanolLevorphanol may increase the serotonergic activities of Citalopram.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Citalopram.
LevothyroxineThe serum concentration of Citalopram can be decreased when it is combined with Levothyroxine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Citalopram.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Citalopram.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Citalopram.
LinezolidLinezolid may increase the serotonergic activities of Citalopram.
LinezolidThe risk or severity of adverse effects can be increased when Citalopram is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.
LiothyronineThe serum concentration of Citalopram can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Citalopram.
LiotrixThe serum concentration of Citalopram can be decreased when it is combined with Liotrix.
LiraglutideCitalopram may increase the hypoglycemic activities of Liraglutide.
LisinoprilThe serum concentration of Citalopram can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Citalopram.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Citalopram.
LofentanilLofentanil may increase the serotonergic activities of Citalopram.
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Citalopram.
LomitapideThe serum concentration of Citalopram can be increased when it is combined with Lomitapide.
LomustineThe metabolism of Lomustine can be decreased when combined with Citalopram.
LoperamideThe serum concentration of Citalopram can be increased when it is combined with Loperamide.
LopinavirCitalopram may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Citalopram.
LoratadineThe metabolism of Loratadine can be decreased when combined with Citalopram.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Citalopram.
LosartanThe serum concentration of Citalopram can be increased when it is combined with Losartan.
LovastatinThe metabolism of Citalopram can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Citalopram.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Citalopram.
Lu AA21004Citalopram may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Citalopram can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Citalopram can be decreased when it is combined with Lumacaftor.
LumefantrineCitalopram may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Citalopram.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.
MacitentanThe metabolism of Macitentan can be decreased when combined with Citalopram.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Citalopram.
MalathionThe metabolism of Malathion can be decreased when combined with Citalopram.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Citalopram.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Citalopram.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Citalopram.
MebanazineMebanazine may increase the serotonergic activities of Citalopram.
MebendazoleThe serum concentration of Citalopram can be increased when it is combined with Mebendazole.
MecaserminCitalopram may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Citalopram.
MefloquineThe serum concentration of Citalopram can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Citalopram can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Citalopram.
MelatoninThe metabolism of Melatonin can be decreased when combined with Citalopram.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Citalopram.
MenadioneThe metabolism of Menadione can be decreased when combined with Citalopram.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Citalopram.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Citalopram.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Citalopram.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Citalopram.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Citalopram.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.
MetforminCitalopram may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the QTc-prolonging activities of Citalopram.
MethadoneThe metabolism of Methadone can be decreased when combined with Citalopram.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Citalopram.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Citalopram.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Citalopram.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Citalopram.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Citalopram.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Citalopram.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Citalopram.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Citalopram.
MethyclothiazideCitalopram may increase the hyponatremic activities of Methyclothiazide.
Methylene blueCitalopram may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Citalopram.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Citalopram.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Citalopram.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Citalopram.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Citalopram.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.
MetolazoneCitalopram may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Citalopram can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Citalopram.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Citalopram.
MianserinThe metabolism of Mianserin can be decreased when combined with Citalopram.
MibefradilThe serum concentration of Citalopram can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Citalopram can be increased when it is combined with Miconazole.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Citalopram.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Citalopram.
MifepristoneMifepristone may increase the QTc-prolonging activities of Citalopram.
MiglitolCitalopram may increase the hypoglycemic activities of Miglitol.
MilnacipranCitalopram may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Citalopram.
MinaprineThe metabolism of Minaprine can be decreased when combined with Citalopram.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Citalopram.
MirabegronThe metabolism of Citalopram can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Citalopram.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Citalopram.
MitomycinThe serum concentration of Citalopram can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Citalopram can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Citalopram can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Citalopram.
MoclobemideMoclobemide may increase the serotonergic activities of Citalopram.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Citalopram.
ModafinilThe serum concentration of Citalopram can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Citalopram.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Citalopram.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Citalopram.
MorphineMorphine may increase the serotonergic activities of Citalopram.
MorphineThe serum concentration of Morphine can be increased when it is combined with Citalopram.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Citalopram.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Citalopram.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Citalopram.
NadololThe serum concentration of Nadolol can be increased when it is combined with Citalopram.
NafcillinThe serum concentration of Citalopram can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Citalopram.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Citalopram.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Citalopram.
NaltrexoneThe serum concentration of Citalopram can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Citalopram.
NaratriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Naratriptan.
NaringeninThe serum concentration of Citalopram can be increased when it is combined with Naringenin.
NateglinideCitalopram may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.
NefazodoneThe serum concentration of Citalopram can be decreased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Citalopram.
NelfinavirThe serum concentration of Citalopram can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Citalopram.
NeostigmineThe serum concentration of Citalopram can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Citalopram can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Citalopram.
NevirapineThe metabolism of Citalopram can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Citalopram.
NicardipineThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Citalopram.
NicotineThe metabolism of Nicotine can be decreased when combined with Citalopram.
NifedipineThe serum concentration of Citalopram can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Citalopram.
NilotinibCitalopram may increase the QTc-prolonging activities of Nilotinib.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Citalopram.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Citalopram.
NisoldipineThe serum concentration of Citalopram can be increased when it is combined with Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.
NitrendipineThe serum concentration of Citalopram can be increased when it is combined with Nitrendipine.
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Citalopram.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Citalopram.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Citalopram.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Citalopram.
NorethisteroneThe serum concentration of Citalopram can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Citalopram.
NormethadoneNormethadone may increase the serotonergic activities of Citalopram.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Citalopram.
OctamoxinOctamoxin may increase the serotonergic activities of Citalopram.
OctreotideCitalopram may increase the hypoglycemic activities of Octreotide.
OctreotideOctreotide may increase the QTc-prolonging activities of Citalopram.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Citalopram.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Citalopram.
OlaparibThe metabolism of Citalopram can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Citalopram.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Citalopram.
OmeprazoleThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Citalopram.
OndansetronThe risk or severity of adverse effects can be increased when Citalopram is combined with Ondansetron.
OndansetronOndansetron may increase the QTc-prolonging activities of Citalopram.
OpiumOpium may increase the serotonergic activities of Citalopram.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Citalopram.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Citalopram.
OsimertinibThe serum concentration of Citalopram can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Citalopram.
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Citalopram.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Citalopram.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Citalopram.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Citalopram.
OxycodoneOxycodone may increase the serotonergic activities of Citalopram.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Citalopram.
OxymorphoneOxymorphone may increase the serotonergic activities of Citalopram.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Citalopram.
OxytocinOxytocin may increase the QTc-prolonging activities of Citalopram.
P-NitrophenolThe serum concentration of Citalopram can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Citalopram can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.
PaliperidoneCitalopram may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Citalopram can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Citalopram.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Citalopram.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Citalopram.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Citalopram.
PantoprazoleThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Citalopram.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Citalopram.
PargylinePargyline may increase the serotonergic activities of Citalopram.
ParoxetineThe serum concentration of Citalopram can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Citalopram.
PasireotideCitalopram may increase the hypoglycemic activities of Pasireotide.
PasireotidePasireotide may increase the QTc-prolonging activities of Citalopram.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.
PazopanibPazopanib may increase the QTc-prolonging activities of Citalopram.
Peginterferon alfa-2bThe serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineCitalopram may increase the hypoglycemic activities of Pentamidine.
PentamidinePentamidine may increase the QTc-prolonging activities of Citalopram.
PentazocinePentazocine may increase the serotonergic activities of Citalopram.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Citalopram.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Citalopram.
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Citalopram.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Citalopram.
PerflutrenPerflutren may increase the QTc-prolonging activities of Citalopram.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Citalopram.
PerindoprilThe serum concentration of Citalopram can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Citalopram.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Citalopram.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Citalopram.
PethidinePethidine may increase the serotonergic activities of Citalopram.
PethidineThe metabolism of Pethidine can be decreased when combined with Citalopram.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Citalopram.
PhenelzinePhenelzine may increase the serotonergic activities of Citalopram.
PhenelzineThe risk or severity of adverse effects can be increased when Citalopram is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Citalopram.
PhenindioneCitalopram may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Citalopram.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Citalopram.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Citalopram.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Citalopram.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Citalopram.
PhenprocoumonCitalopram may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Citalopram.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Citalopram.
PimozideThe risk or severity of adverse effects can be increased when Citalopram is combined with Pimozide.
PimozidePimozide may increase the QTc-prolonging activities of Citalopram.
PindololThe metabolism of Pindolol can be decreased when combined with Citalopram.
PioglitazoneCitalopram may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Citalopram.
PiperazineThe metabolism of Piperazine can be decreased when combined with Citalopram.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Citalopram.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.
PirlindolePirlindole may increase the serotonergic activities of Citalopram.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Citalopram.
PivhydrazinePivhydrazine may increase the serotonergic activities of Citalopram.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Citalopram.
Platelet Activating FactorThe serum concentration of Citalopram can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Citalopram.
PolythiazideCitalopram may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Citalopram.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Citalopram.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Citalopram.
PosaconazoleThe serum concentration of Citalopram can be increased when it is combined with Posaconazole.
PramlintideCitalopram may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Citalopram.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Citalopram.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Citalopram.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Citalopram.
PrazosinThe serum concentration of Citalopram can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Citalopram.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Citalopram.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Citalopram.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Citalopram.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Citalopram.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Citalopram.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Citalopram.
PrimidoneThe metabolism of Primidone can be decreased when combined with Citalopram.
ProbenecidThe serum concentration of Citalopram can be increased when it is combined with Probenecid.
ProcainamideCitalopram may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Citalopram.
ProcarbazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Citalopram.
ProgesteroneThe serum concentration of Citalopram can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Citalopram.
ProguanilThe metabolism of Proguanil can be decreased when combined with Citalopram.
PromazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Promazine.
PromazinePromazine may increase the QTc-prolonging activities of Citalopram.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Citalopram.
PromethazineThe metabolism of Promethazine can be decreased when combined with Citalopram.
PropafenonePropafenone may increase the QTc-prolonging activities of Citalopram.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Citalopram.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram.
PropericiazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Citalopram.
PropofolThe metabolism of Propofol can be decreased when combined with Citalopram.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Citalopram.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Citalopram.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Citalopram.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Citalopram.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Citalopram.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Citalopram.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Citalopram.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Citalopram.
QuazepamThe metabolism of Quazepam can be decreased when combined with Citalopram.
QuercetinThe serum concentration of Citalopram can be increased when it is combined with Quercetin.
QuetiapineCitalopram may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Citalopram can be increased when it is combined with Quinacrine.
QuinethazoneCitalopram may increase the hyponatremic activities of Quinethazone.
QuinidineCitalopram may increase the QTc-prolonging activities of Quinidine.
QuinineCitalopram may increase the QTc-prolonging activities of Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Citalopram.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Citalopram.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Citalopram.
RanitidineThe serum concentration of Citalopram can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Citalopram.
RasagilineRasagiline may increase the serotonergic activities of Citalopram.
RasagilineThe metabolism of Rasagiline can be decreased when combined with Citalopram.
ReboxetineThe serum concentration of Citalopram can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Citalopram can be increased when it is combined with Regorafenib.
RemifentanilRemifentanil may increase the serotonergic activities of Citalopram.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Citalopram.
RepaglinideCitalopram may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Citalopram.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Citalopram.
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Citalopram.
RifabutinThe metabolism of Citalopram can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Citalopram can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Citalopram.
RifapentineThe metabolism of Citalopram can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Citalopram.
RilpivirineThe serum concentration of Citalopram can be increased when it is combined with Rilpivirine.
RiluzoleThe metabolism of Riluzole can be decreased when combined with Citalopram.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Citalopram.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Citalopram.
RitonavirThe serum concentration of Citalopram can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Citalopram.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Citalopram.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Citalopram.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Citalopram.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Citalopram.
RolapitantThe serum concentration of Citalopram can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Citalopram.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Citalopram.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Citalopram.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Citalopram.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Citalopram.
RosiglitazoneCitalopram may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Citalopram.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Citalopram.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram.
SafrazineSafrazine may increase the serotonergic activities of Citalopram.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Citalopram.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Citalopram.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Citalopram.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Citalopram.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Citalopram.
SaxagliptinCitalopram may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.
SelegilineSelegiline may increase the serotonergic activities of Citalopram.
SelegilineThe metabolism of Selegiline can be decreased when combined with Citalopram.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Citalopram.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Citalopram.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Citalopram.
SertralineThe serum concentration of Citalopram can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Citalopram.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Citalopram.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Citalopram.
SildenafilThe metabolism of Citalopram can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Citalopram.
SiltuximabThe serum concentration of Citalopram can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Citalopram can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Citalopram can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Citalopram.
SirolimusThe serum concentration of Citalopram can be decreased when it is combined with Sirolimus.
SitagliptinCitalopram may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Citalopram.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Citalopram.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Citalopram.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Citalopram.
SotalolCitalopram may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Citalopram.
SparteineThe metabolism of Sparteine can be decreased when combined with Citalopram.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Citalopram.
SpironolactoneThe serum concentration of Citalopram can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Citalopram can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Citalopram can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Citalopram.
StreptozocinThe serum concentration of Citalopram can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the serotonergic activities of Citalopram.
SulfadiazineCitalopram may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleCitalopram may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Citalopram.
SulfinpyrazoneThe serum concentration of Citalopram can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleCitalopram may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Citalopram.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Citalopram.
SumatriptanThe serum concentration of Citalopram can be increased when it is combined with Sumatriptan.
SumatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Sumatriptan.
SunitinibCitalopram may increase the hypoglycemic activities of Sunitinib.
SunitinibThe serum concentration of Citalopram can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Citalopram.
TacrineThe serum concentration of Citalopram can be increased when it is combined with Tacrine.
TacrineThe metabolism of Tacrine can be decreased when combined with Citalopram.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Citalopram.
TacrolimusThe serum concentration of Citalopram can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Citalopram can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Citalopram.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Citalopram.
TapentadolTapentadol may increase the serotonergic activities of Citalopram.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Citalopram.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Citalopram.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Citalopram.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Citalopram.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Citalopram.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Citalopram is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Citalopram.
TelaprevirThe metabolism of Citalopram can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Citalopram.
TelavancinTelavancin may increase the QTc-prolonging activities of Citalopram.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Citalopram.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Citalopram.
TelmisartanThe serum concentration of Citalopram can be increased when it is combined with Telmisartan.
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Citalopram.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Citalopram.
TemazepamThe metabolism of Temazepam can be decreased when combined with Citalopram.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Citalopram.
TeniposideThe metabolism of Teniposide can be decreased when combined with Citalopram.
TerazosinThe serum concentration of Citalopram can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Citalopram.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Citalopram.
TerfenadineThe serum concentration of Citalopram can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Citalopram.
TesmilifeneThe serum concentration of Citalopram can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Citalopram.
TestosteroneThe serum concentration of Citalopram can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Citalopram.
TetrabenazineCitalopram may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Citalopram.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Citalopram.
TheobromineThe metabolism of Theobromine can be decreased when combined with Citalopram.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Citalopram.
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Citalopram.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Citalopram.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram.
ThioproperazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Citalopram.
ThioridazineThioridazine may increase the QTc-prolonging activities of Citalopram.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Citalopram.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Citalopram.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Citalopram.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Citalopram.
TiclopidineThe metabolism of Citalopram can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Citalopram.
TimololThe serum concentration of Timolol can be increased when it is combined with Citalopram.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Citalopram.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Citalopram.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Citalopram.
TocilizumabThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Citalopram.
TolazamideCitalopram may increase the hypoglycemic activities of Tolazamide.
TolbutamideCitalopram may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.
ToloxatoneToloxatone may increase the serotonergic activities of Citalopram.
TolterodineTolterodine may increase the QTc-prolonging activities of Citalopram.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Citalopram.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Citalopram.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Citalopram.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Citalopram.
ToremifeneCitalopram may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Citalopram.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Citalopram.
TramadolTramadol may increase the serotonergic activities of Citalopram.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Citalopram.
TranylcypromineTranylcypromine may increase the serotonergic activities of Citalopram.
TranylcypromineThe risk or severity of adverse effects can be increased when Citalopram is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Citalopram.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Citalopram.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Citalopram.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Citalopram.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Citalopram.
TriamtereneThe metabolism of Triamterene can be decreased when combined with Citalopram.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.
TrichlormethiazideCitalopram may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Citalopram.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Citalopram.
TrimethoprimThe serum concentration of Citalopram can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Citalopram.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Citalopram.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Citalopram.
TroleandomycinThe serum concentration of Citalopram can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Citalopram.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Citalopram.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Citalopram.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Citalopram.
VandetanibCitalopram may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Citalopram.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Citalopram.
VemurafenibCitalopram may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Citalopram can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Citalopram.
VerapamilThe metabolism of Citalopram can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Citalopram.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.
VilanterolVilanterol may increase the QTc-prolonging activities of Citalopram.
VilazodoneVilazodone may increase the serotonergic activities of Citalopram.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Citalopram.
VinblastineThe serum concentration of Citalopram can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Citalopram.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Citalopram.
VincristineThe serum concentration of Citalopram can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Citalopram can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Citalopram.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Citalopram.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Citalopram.
VorinostatVorinostat may increase the QTc-prolonging activities of Citalopram.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Citalopram.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Citalopram.
WarfarinCitalopram may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Citalopram.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Citalopram.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Citalopram.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Citalopram.
ZileutonThe metabolism of Zileuton can be decreased when combined with Citalopram.
ZimelidineCitalopram may increase the serotonergic activities of Zimelidine.
ZimelidineThe serum concentration of Citalopram can be increased when it is combined with Zimelidine.
ZiprasidoneCitalopram may increase the QTc-prolonging activities of Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Citalopram.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Citalopram.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Citalopram.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Citalopram.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Citalopram.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Citalopram.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Citalopram.
ZuclopenthixolCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology. 1999 Mar;20(3):287-96. [PubMed:10063489 ]
  2. Maines LW, Keck BJ, Smith JE, Lakoski JM: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999 Apr;32(1):58-66. [PubMed:10188639 ]
  3. Vicentic A, Battaglia G, Carroll FI, Kuhar MJ: Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res. 1999 Sep 11;841(1-2):1-10. [PubMed:10546982 ]
  4. Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM: Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine. Synapse. 2001 Feb;39(2):109-21. [PubMed:11180498 ]
  5. Dutta AK, Fei XS, Beardsley PM, Newman JL, Reith ME: Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. J Med Chem. 2001 Mar 15;44(6):937-48. [PubMed:11300876 ]
  6. Plenge P, Wiborg O: High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett. 2005 Aug 5;383(3):203-8. Epub 2005 Apr 25. [PubMed:15955412 ]
  7. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008 ]
  8. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  9. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
  10. Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology. 2009 Sep;57(3):287-94. doi: 10.1016/j.neuropharm.2009.05.009. Epub 2009 Jun 3. [PubMed:19500602 ]
  11. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  2. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017. [PubMed:18215618 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23